Compositions comprising nebivolol
First Claim
Patent Images
1-1. ) The composition of claim 1 wherein at least one of the other active agents is a cardiovascular agent.
4 Assignments
0 Petitions
Accused Products
Abstract
Nebivolol has been shown to be beneficial in the treatment of cardiovascular diseases such hypertension, congestive heart failure, arterial stiffness and endothelial dysfunction. The present invention features a pharmaceutical composition comprising nebivolol and at least one other active agent, wherein the at least one other active agent is a cardiovascular agent.
-
Citations
35 Claims
-
1-1. ) The composition of claim 1 wherein at least one of the other active agents is a cardiovascular agent.
- 2. ) The composition of claim 2 wherein the cardiovascular agent is selected from the group consisting of ACE inhibitors, ARB'"'"'s, adrenergic blockers, adrenergic agonists, agents for pheochromocytoma, antiarrhythmics, antiplatelet agents, anticoagulants, antihypertensives, antilipemic agents, antidiabetics, antiinflammatory agents, calcium channel blockers, CETP inhibitors, COX-2 inhibitors, direct thrombin inhibitors, diuretics, endothelin receptor antagonists, HMG Co-A reductase inhibitors, inotropic agents, rennin inhibitors, vasodialators, vasopressors, AGE crosslink breakers, AGE formation inhibitors, and mixtures thereof.
- 4. ) The composition of claim 4, wherein the cardiovascular agent is an ACE inhibitor.
- 5. ) The composition of claim 5 wherein the ACE inhibitor is selected from the group consisting of alacepril, benazepril, captopril, ceronapril, cilazapril, delapril, enalapril, enalaprilat, fosinopril, imidapril, lisinopril, perindopril, quinapril, ramipril, ramiprilat, spirapril, temocapril, trandolapril, and mixtures thereof.
-
8. ) The composition of claim 8 wherein the ARB is selected from the group consisting of candesartan, eprosartan, irbesartan, losartan, valsartan, and mixtures thereof.
-
10. ) A composition comprising nebivolol and only one other active agent.
-
11. ) The composition of claim 11 wherein the other active agent is a cardiovascular agent.
- 12. ) The composition of claim 12 wherein the cardiovascular agent is selected from the group consisting of ACE inhibitors, ARB'"'"'s, adrenergic blockers, adrenergic agonists, agents for pheochromocytoma, antiarrhythmics, antiplatelet agents, anticoagulants, antihypertensives, antilipemic agents, antidiabetics, antiinflammatory agents, calcium channel blockers, CETP inhibitors, COX-2 inhibitors, direct thrombin inhibitors, diuretics, endothelin receptor antagonists, HMG Co-A reductase inhibitors, inotropic agents, rennin inhibitors, vasodialators, vasopressors, AGE crosslink breakers, AGE formation inhibitors, and mixtures thereof.
-
17. ) A pharmaceutical composition comprising nebivolol and at least one other active agent, and a pharmaceutically-acceptable carrier.
- 18. ) The pharmaceutical composition of claim 18 wherein at least one of the other active agents is a cardiovascular agent.
- 19. ) The pharmaceutical composition of claim 19 wherein the cardiovascular agent is selected from the group consisting of ACE inhibitors, ARB'"'"'s, adrenergic blockers, adrenergic agonists, agents for pheochromocytoma, antiarrhythmics, antiplatelet agents, anticoagulants, antihypertensives, antilipemic agents, antidiabetics, antiinflammatory agents, calcium channel blockers, CETP inhibitors, COX-2 inhibitors, direct thrombin inhibitors, diuretics, endothelin receptor antagonists, HMG Co-A reductase inhibitors, inotropic agents, rennin inhibitors, vasodialators, vasopressors, AGE crosslink breakers, AGE formation inhibitors, and mixtures thereof.
- 21. ) The pharmaceutical composition of claim 21, wherein the cardiovascular agent is an ACE inhibitor.
-
22. ) The pharmaceutical composition of claim 22 wherein the ACE inhibitor is selected from the group consisting of alacepril, benazepril, captopril, ceronapril, cilazapril, delapril, enalapril, enalaprilat, fosinopril, imidapril, lisinopril, perindopril, quinapril, ramipril, ramiprilat, spirapril, temocapril, trandolapril, and mixtures thereof.
-
23. ) The pharmaceutical composition of claim 23 wherein the ACE inhibitor is selected from the group consisting of enalapril, ramipril and ramiprilat and mixtures thereof
-
25. ) The pharmaceutical composition of claim 25 wherein the ARB is selected from the group consisting of candesartan, eprosartan, irbesartan, losartan, valsartan, and mixtures thereof.
-
27. ) A method of treating and/or preventing a cardiovascular disorder comprising administering to a subject a therapeutically effective amount of nebivolol and at least one other active agent.
- 28. ) The method of claim 28 wherein the at least one other active agent is a cardiovascular agent.
-
29. ) The method of claim 29 wherein the cardiovascular agent is selected from the group consisting of ACE inhibitors, ARB'"'"'s, adrenergic blockers, adrenergic agonists, agents for pheochromocytoma, antiarrhythmics, antiplatelet agents, anticoagulants, antihypertensives, antilipemic agents, antidiabetics, antiinflammatory agents, calcium channel blockers, CETP inhibitors, COX-2 inhibitors, direct thrombin inhibitors, diuretics, endothelin receptor antagonists, HMG Co-A reductase inhibitors, inotropic agents, rennin inhibitors, vasodialators, vasopressors, AGE crosslink breakers, AGE formation inhibitors, and mixtures thereof.
- 32. ) The method of claim 32 wherein the cardiovascular agent is an ACE inhibitor.
Specification